Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

PURPOSE: Both gain-of-function EZH2 mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC) derived lymphomas. We hypothesized that direct inhibition of EZH2 and HDAC would be synergistic in GC-derive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lue, Jennifer K., Prabhu, Sathyen A., Liu, Yuxuan, Gonzalez, Yulissa, Verma, Akanksha, Mundi, Prabhjot S., Abshiru, Nebiyu, Camarillo, Jeannie M., Mehta, Swasti, Chen, Emily I., Qiao, Changhong, Nandakumar, Renu, Cremers, Serge, Kelleher, Neil L., Elemento, Olivier, Amengual, Jennifer E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726529/
https://ncbi.nlm.nih.gov/pubmed/30979734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3989
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados